GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Shiller PE Ratio

EDIT (Editas Medicine) Shiller PE Ratio : (As of Apr. 27, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Editas Medicine Shiller PE Ratio Historical Data

The historical data trend for Editas Medicine's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Shiller PE Ratio Chart

Editas Medicine Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Editas Medicine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Editas Medicine's Shiller PE Ratio

For the Biotechnology subindustry, Editas Medicine's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Editas Medicine's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Editas Medicine's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Editas Medicine's Shiller PE Ratio falls into.


;
;

Editas Medicine Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Editas Medicine's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Editas Medicine's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.55/133.1571*133.1571
=-0.550

Current CPI (Dec. 2024) = 133.1571.

Editas Medicine Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -0.349 99.621 -0.466
201506 -3.087 100.684 -4.083
201509 -0.486 100.392 -0.645
201512 -0.357 99.792 -0.476
201603 -0.800 100.470 -1.060
201606 -0.540 101.688 -0.707
201609 -0.590 101.861 -0.771
201612 -1.100 101.863 -1.438
201703 -0.850 102.862 -1.100
201706 -0.650 103.349 -0.837
201709 -0.640 104.136 -0.818
201712 -0.840 104.011 -1.075
201803 -0.670 105.290 -0.847
201806 -0.820 106.317 -1.027
201809 -0.320 106.507 -0.400
201812 -0.520 105.998 -0.653
201903 -0.600 107.251 -0.745
201906 -0.690 108.070 -0.850
201909 -0.660 108.329 -0.811
201912 -0.740 108.420 -0.909
202003 -0.690 108.902 -0.844
202006 -0.430 108.767 -0.526
202009 0.120 109.815 0.146
202012 -1.000 109.897 -1.212
202103 -0.860 111.754 -1.025
202106 -0.810 114.631 -0.941
202109 -0.570 115.734 -0.656
202112 -0.610 117.630 -0.691
202203 -0.740 121.301 -0.812
202206 -0.780 125.017 -0.831
202209 -0.810 125.227 -0.861
202212 -0.880 125.222 -0.936
202303 -0.710 127.348 -0.742
202306 -0.560 128.729 -0.579
202309 -0.550 129.860 -0.564
202312 -0.230 129.419 -0.237
202403 -0.760 131.776 -0.768
202406 -0.820 132.554 -0.824
202409 -0.750 133.029 -0.751
202412 -0.550 133.157 -0.550

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Editas Medicine  (NAS:EDIT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Editas Medicine Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Editas Medicine's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
Linda Burkly officer: EVP, CHIEF SCIENTIFIC OFFICER 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill director, officer: CEO 215 FIRST STREET, CAMBRIDGE MA 02142
Erick Lucera officer: EVP, CHIEF FINANCIAL OFFICER 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Baisong Mei officer: SVP, CHIEF MEDICAL OFFICER C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bruce Eaton officer: EVP, Chief Business Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michelle Robertson officer: Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman officer: EVP, Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels officer: EVP/Chief Medical Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton director C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen director 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142